Mineralys Therapeutics (MLYS) Change in Acquisitions & Divestments (2022 - 2026)

Mineralys Therapeutics has reported Change in Acquisitions & Divestments over the past 5 years, most recently at $302.5 million for Q1 2026.

• Change in Acquisitions & Divestments reached $302.5 million in Q1 2026 per MLYS's latest filing, up from $165.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $302.5 million in Q1 2026 and bottomed at $22.5 million in Q1 2023.
• Median Change in Acquisitions & Divestments over the past 5 years was $71.2 million (2024), compared with a mean of $103.8 million.
• The largest annual shift saw Change in Acquisitions & Divestments tumbled 48.15% in 2025 before it soared 764.29% in 2026.
• Over 5 years, Change in Acquisitions & Divestments stood at $50.0 million in 2022, then rose by 30.0% to $65.0 million in 2023, then surged by 126.92% to $147.5 million in 2024, then rose by 11.86% to $165.0 million in 2025, then soared by 83.33% to $302.5 million in 2026.
• Business Quant data shows Change in Acquisitions & Divestments for MLYS at $302.5 million in Q1 2026, $165.0 million in Q4 2025, and $150.0 million in Q3 2025.

Peer Comparison